Skip to content

Study · In vitro (cells) · mouse · 2026

4 results

NNT inhibits microglial activation via mitochondrial oxidative stress in spinal cord injury.

Li M, Gu Q, Fan Z, Duan C

Neuroscience letters5 Dec 2025

PMID41354204 (opens in a new tab)DOI10.1016/j.neulet.2025.138486 (opens in a new tab)PepBankPUB-41354204
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In BV2 microglial cells, the mitochondria-targeting peptide SS‑31 reduced mitochondrial superoxide levels.

    In plain wordsIn cells, the peptide SS‑31 lowered superoxide levels in mitochondria, the cell's energy units.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial superoxide level
    Study

    mousen: not reported in source

    BV2 microglial cells
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, treatment with the mitochondria-targeting peptide SS-31 reduced mitochondrial superoxide levels.
    1 context sentence
    Summary · context
    In vitro, lipopolysaccharide (LPS) induced microglial activation and increased NNT expression in BV2 cells.
  2. 02LabIn vitro (cells)Mechanism

    In BV2 cells with NNT deficiency, SS‑31 suppressed the inflammatory response.

    In plain wordsIn cells lacking the NNT protein, SS‑31 reduced signs of inflammation.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInflammatory response with NNT deficiency
    Study

    mousen: not reported in source

    BV2 microglial cells
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 also suppressed the inflammatory, proliferative, and oxidative stress responses caused by NNT deficiency in BV2 cells.
    1 context sentence
    Summary · context
    In vitro, lipopolysaccharide (LPS) induced microglial activation and increased NNT expression in BV2 cells.
  3. 03LabIn vitro (cells)Mechanism

    In BV2 cells with NNT deficiency, SS‑31 suppressed the proliferative response.

    In plain wordsIn cells lacking the NNT protein, SS‑31 reduced excess cell growth.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseProliferative response with NNT deficiency
    Study

    mousen: not reported in source

    BV2 microglial cells
    Outcome group
    Cell proliferation and differentiation · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 also suppressed the inflammatory, proliferative, and oxidative stress responses caused by NNT deficiency in BV2 cells.
    1 context sentence
    Summary · context
    In vitro, lipopolysaccharide (LPS) induced microglial activation and increased NNT expression in BV2 cells.
  4. 04LabIn vitro (cells)Mechanism

    In BV2 cells with NNT deficiency, SS‑31 suppressed the oxidative stress response.

    In plain wordsIn cells lacking the NNT protein, SS‑31 reduced signs of oxidative stress.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseOxidative stress response with NNT deficiency
    Study

    mousen: not reported in source

    BV2 microglial cells
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SS-31 also suppressed the inflammatory, proliferative, and oxidative stress responses caused by NNT deficiency in BV2 cells.
    1 context sentence
    Summary · context
    In vitro, lipopolysaccharide (LPS) induced microglial activation and increased NNT expression in BV2 cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.